VEGF-Antikörper in der Therapie der Frühgeborenenretinopathie

Zusammenfassung

Die Frühgeborenenretinopathie zählt zu den 3 häufigsten Erblindungsursachen der Kindheit in Industrienationen. Immer weiter verbesserte Möglichkeiten der neonatologischen Versorgung haben zu einer erhöhten Überlebenswahrscheinlichkeit immer unreiferer Kinder geführt, die wiederum ein erhöhtes Risiko haben, eine Frühgeborenenretinopathie zu entwickeln. Die bisher etablierte Laserkoagulation in der Therapie der Frühgeborenenretinopathie führt bei einem zeitgerechten Einsatz zu einer guten Rückbildung der pathologischen Gefäßneubildungen und kann dadurch die Entwicklung einer Netzhautablösung verhindern. Die Koagulation der avaskulären Netzhautareale führt jedoch zu einer Vernarbung dieser Netzhautbereiche und unterstützt die weitere Netzhautentwicklung nicht. Seit jüngster Zeit gibt es erste vielversprechende Berichte über den intravitrealen Einsatz von VEGF-Antikörpern bei der Frühgeborenenretinopathie. Die vorliegende Arbeit berichtet über eigene Erfahrungen mit dieser Therapie und möchte einen Überblick über den derzeitigen Stand der Literatur zu diesem Thema geben.

Abstract

Retinopathy of prematurity (ROP) is one of the three leading causes of legal blindness in childhood in the developed countries. Improved neonatal care has resulted in the increased survival of extremely immature infants at high risk to develop ROP. Current treatment for ROP with laser may prevent blindness by causing involution of pathological vessels and thus inhibit the development of retinal detachment. But this coagulation of the avascular retina is a destructive therapy and does not otherwise ameliorate retinal development. Recent reports have described vascular endothelial growth factor antibodies as therapy for ROP. This article reports our own experience with this new therapy and gives an overview of the recent literature.

Frühgeborenenretinopathie - Anti-VEGF - Bevacizumab - vascular endothelial growth factor

retinopathy of prematurity - anti-VEGF - bevacizumab - vascular endothelial growth factor

Literatur

• 1 An International Committee for the Classification of Retinopathy of Prematurity . The International Classification of Retinopathy of Prematurity revisited.  Arch Ophthalmol. 2005;  123 991-999
• 2 Arevalo J F, Maia M, Flynn H W et al. Tractional retinal detzachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.  Br J Ophthalmol. 2008;  92 213-216
• 3 Axer-Siegel Jr R, Maharshak I, Snir M et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes.  Retina. 2008;  28 839-846
• 4 Brennan R, Gnanaraj L, Cottrell D G. Retinopathy of prematurity in practice. I: screening for threshold disease.  Eye. 2003;  17 183-188
• 5 Capone Jr A, Diaz-Rohena R, Sternberg Jr P et al. Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity.  Am J Ophthalmol. 1993;  116 444-450
• 6 Chung E, Kim J, Ahn H et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.  Graefes Arch Clin Exp Ophthalmology. 2007;  245 1727-1730
• 7 Connolly B P, Ng E Y, McNamara J A et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome.  Ophthalmology. 2002;  109 936-941
• 8 Cryotherapy for Retinopathy of Prematurity Cooperative Group . Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminiary results.  Arch Ophthalmol. 1988;  106 471-479
• 9 Cryotherapy for Retinopathy of Prematurity Cooperative Group . Multicenter trial of cryotherapy for retinopathy of prematurity. Final results. 15-year outcomes following threshold retinopathy.  Arch Ophthalmol. 2005;  123 311-318
• 10 Cunningham S, Fleck B W, Elton R A et al. Transcutanous oxygen levels in retinopathy of prematurity.  Lancet. 1995;  346 1464-1465
• 11 Field D, Dorling J, Manktelow B et al. Survival of extreme premature babies in a geographically defined population: prospective cohort study of 1994 – 9 compared with 2000 – 5.  BMJ. 2008;  336 1221-1223
• 12 Fleck B W, McIntosh N. Pathogenesis of retinopathy of prematurity and possible preventive strategies.  Early Human Development. 2008;  84 83-88
• 13 Giannantonio C, Papacci P, Molle F et al. An epidemiological analysis of retinopathy of prematurity over ten years.  J Pediatr Ophthalmol Strabismus. 2008;  45 162-167
• 14 Hellström A, Ley D, Hansen-Pupp I et al. New insights into the development of retinopathy of prematurity – importance of early weight gain.  Acta Paediatrica. 2010;  99 502-508
• 15 Holmstrom G, el Azazi M, Kugelberg U. Ophthalmological follow up of preterm infants: a population based, prospective study of visual acuity and strabismus.  Br J Ophthalmol. 1999;  83 143-150
• 16 Honda S, Hirabayashi H, Tsukahara Y et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.  Graefes Arch Clin Exp Ophthalmol. 2008;  246 1061-1063
• 17 Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis.  Invest Ophthalmol Vis Sci. 2000;  41 1217-1228
• 18 Jandeck C, Kellner U, Heimann H et al. Koagulatioinstherapie der Frühgeborenenretinopathie: Vergleich der anatomischen und funktionellen Ergebnisse nach Laser- oder Kryokoagulation.  Ophthalmologe. 2005;  102 33-38
• 19 Jandeck C, Kellner U, Heimann H et al. Frühgeborenenretinopathie-Screening: Ergebnisse eines Zentrums zwischen 1991 und 2002.  Klin Monatsbl Augenheilkd. 2005;  222 577-585
• 20 Jandeck C, Kellner U, Lorenz B et al. Arbeitsgruppe der Retinologischen Gesellschaft zur Erstellung der Leitlinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen. Augenärztliche Screening-Untersuchung von Frühgeborenen.  Klin Monatsbl Augenheilkd. 2008;  225 123-130
• 21 Jandeck C. Neue therapeutische Ansätze in der Behandlung Frühgeborenenretinopathie.  Klin Monatsbl Augenheilkd. 2009;  226 914-920
• 22 Kusaka S, Shima C, Wada K et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.  Br J Ophthalmol. 2008;  92 1450-1455
• 23 Lad E, Nguyen T, Morton J et al. Retinopathy of prematurity in the United States.  Br J Ophthalmol. 2008;  92 320-325
• 24 Law J C, Recchia F M, Morrison D G et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.  J AAPOS. 2010;  14 6-10
• 25 Lalwani G, Berrocal A, Murray T et al. Off-Label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.  Retina. 2008;  28 13-18
• 26 Larsson E, Carle-Petrelius B, Cernerud G et al. Incidence of ROP in two consecutive Swedish Population based studies.  Br J Ophthalmol. 2002;  86 1122-1126
• 27 Löfqvist C, Anderson E, Sigurdsson J et al. Longitudinal postnatal weight and Insulin-like Growth Factor I measurements in prediction Retinopathy of Prematurity.  Arch Ophthalmol. 2006;  124 1711-1718
• 28 Mc Colm J R, Cunningham S, Wade J et al. Hypoxic oxygen fluctuations produce less severe retinopathy of prematurity.  Pediatr Res. 2004;  55 107-113
• 29 Mintz-Hittner H, Kuffel R. intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.  Retina. 2008;  28 831-838
• 30 Mintz-Hittner H. BEAT-ROP study (bevacizumab eliminates the angiogenic threat of ROP: Clinical trials.gov Identifier: NCT 0 062 726). 2009 (Stand: Phase II recruiting). http://www.Clinicaltrials.gov
• 31 Mintz-Hittner H A, Best L M. Antivascular endothelial growth factor for retinopathy of prematurity.  Curr Opin Pediatr. 2009;  21 182-187
• 32 Mintz-Hittner H A. Avastin as monotherapy for retinopathy of prematurity.  J AAPOS. 2010;  14 2-3
• 33 Nazari H, Modarres M, Parvaresh M M et al. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.  Graefes Arch Clin Exp Ophthalmol. 2010;  ; Epub ahead
• 34 Ng E Y, Connolly B P, McNamara J A et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome.  Ophthalmology. 2002;  109 928-934, discussion 35
• 35 Paysse E A, Lindsey J L et al. Therapeutic outcomes of cryotherapy versus transpupillary diode laser photocoagulation for threshold retinopathy of prematurity.  J AAPOS. 1999;  3 234-240
• 36 Reynolds J D, Dobson V, Quinn G E et al. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies.  Arch Ophthalmol. 2002;  120 1470-1476
• 37 Smith L E, Shen W, Perruzzi C et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularisation by insulin-like growth factor-1 receptor.  Nat Med. 1999;  5 1390-1395
• 38 Smith L E. Through the eyes of a child: understanding retinopathy through ROP – the Friedenwald lecture.  Invest Ophthalmol Vis Sci. 2008;  49 5177-5182
• 39 Sonmez K, Drenser K, Capone A et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.  Ophthalmology. 2008;  115 1065-1070
• 40 The Laser ROP Study Group . Laser therapy for retinopathy of prematurity.  Arch Ophthalmol. 1994;  12 154-156
• 41 Travassos A, Teixeira S, Ferreira P et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.  Ophthalmic Surg Lasers imaging. 2007;  38 233-237
• 42 Trese M. BLOCK-ROP study. 2009 Identifier: NCT00702819 (Stand: Phase II Recruiting). http://www.ClinicalTrials.gov
• 43 White J E, Repka M X. Randomized comparison of diode laser photocoagulation verus cryotherapy for threshold retinopathy of prematurity: 3-year outcome.  J Pediatr Ophthalmol Strabismus. 1997;  34 83-87